Gamida Cell Ltd.
Harey Yehuda 54
P.O.B. 94
Savyon
56530
Tel: 03-534-7482
Fax: 03-534-3067
203 articles about Gamida Cell Ltd.
-
Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa
10/10/2022
Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa.
-
Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting
9/29/2022
Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting.
-
Gamida Cell Announces Entry into Commitment Letter with Highbridge for $25 Million Financing
9/28/2022
Gamida Cell Ltd. announced that it has entered into a Commitment Letter with certain funds managed by Highbridge Capital Management, LLC, pursuant to which Highbridge has committed to provide a $25 million senior secured, convertible term loan.
-
Gamida Cell Announces Launch of Public Offering of Ordinary Shares - September 27, 2022
9/27/2022
Gamida Cell Ltd., the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, announced the launch of a follow-on public offering of its ordinary shares.
-
Seven biopharma companies are under new leadership. This week's Movers & Shakers highlights these new chief executive officers who aim to guide their companies into the future.
-
Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies
9/19/2022
Gamida Cell Ltd. today announced that Abigail “Abbey” L. Jenkins, MS, has joined as President & CEO.
-
Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting
9/12/2022
Gamida Cell Ltd. today announced the presentation of data supporting the potential of omidubicel for the treatment of patients with blood cancers in need of an allogeneic hematopoietic stem cell transplant at the 2022 Cord Blood Connect Meeting, being held in South Beach, Florida.
-
Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update
8/15/2022
Gamida Cell today provided a business update and reported financial results for the quarter ended June 30, 2022.
-
Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
8/10/2022
Gamida Cell Ltd. announces dosing of the first patient in a company-sponsored Phase 1/2 study evaluating a cryopreserved, readily available formulation of GDA-201 for the treatment of follicular and diffuse large B cell lymphomas (NCT05296525).
-
Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast
8/8/2022
Gamida Cell Ltd. today announced that the company will host a conference call and live audio webcast on Monday, August 15, 2022, at 8:00 a.m. ET to review its second quarter 2022 financial results and provide an update on the company.
-
The FDA has had a busy week, accepting drug applications, approving clinical trials and granting various special designations for Gamida Cell, Cellectis, Scynexis & more.
-
The FDA granted Priority Review for omidubicel with a target action date of January 30, 2023. Omidubicel is a first-in-class, advanced NAM (nicotinamide)-enabled stem cell therapy.
-
Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review
8/1/2022
Gamida Cell Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s Biologics License Application (BLA) for omidubicel for the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant.
-
Black/African American hematological cancer patients tend to have the worst outcomes. This is partly driven by a lack of access to allogeneic hematopoietic stem cell transplant and available donors.
-
Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference
6/13/2022
Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces that company management will present its corporate highlights at the JMP Securities Life Sciences Conference, June 16, 2022 with a presentation at 2:00 p.m. ET in New York, NY.
-
Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel
6/2/2022
Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel.
-
Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference - June 01, 2022
6/1/2022
Gamida Cell Ltd. announces that company management will present its corporate highlights at the Jefferies Healthcare Conference, June 8, 2022 with a presentation at 11:00 a.m. ET in New York, NY.
-
Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
6/1/2022
Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, today announced the activation of the initial clinical sites to screen and enroll patients in the company-sponsored Phase 1/2 study evaluating a cryopreserved formulation of GDA-201.
-
Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences Conference
5/17/2022
Gamida Cell Ltd., the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, announced that company management will present at the upcoming H.C. Wainwright Global Life Sciences Conference.
-
Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update
5/10/2022
Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today provided a business update and reported financial results for the quarter ended March 31, 2022.